Pradeep J. Poonnen

Pradeep J. Poonnen

Auto-generated profile, based on publicly available information

Pradeep J. Poonnen

Durham Veterans Affairs Medical Center, Division of Hematology and Oncology, Durham, NC

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in JCO Oncology Practice
Verified
Journal Article
Closed access
VVVishal Vashistha
Vishal Vashistha
JAJenna Armstrong
Jenna Armstrong
DWDavid Winski
David Winski
PPPradeep J. Poonnen
Pradeep J. Poonnen
BHBradley Hintze
Bradley Hintze
MKMichael J. Kelley
Michael J. Kelley
PURPOSE: Next-generation sequencing (NGS) gene panels are frequently completed for patients with advanced non–small-cell lung cancer (NSCLC). Patients with highly actionable gene variants have improved outcomes and reduced toxicities with the use of corresponding targeted agents. We sought to identify barriers to targeted agent use within the Veterans Health Affairs' National Precision Oncology Program (NPOP). METHODS: A retrospective evaluation of patients with NSCLC who underwent NGS multigene panels through NPOP between July 2015 and February 2019 was conducted. Patients who were assigned level 1 or 2A evidence for oncogenic gene variants by an artificial intelligence offering (IBM Watson for Genomics [WfG]) and NPOP staff were selected. Antineoplastic drug prescriptions and provider notes were reviewed. Reasons for withholding targeted treatments were categorized. RESULTS: Of 1,749 patients with NSCLC who successfully underwent NGS gene panel testing, 112 (6.4%) patients were assigned level 1 and/or 2A evidence for available targeted treatments by WfG and NPOP staff. All highly actionable gene variants were within ALK, BRAF, EGFR, ERBB2, MET, RET, and ROS1. Of these, 36 (32.1%) patients were not prescribed targeted agents. The three most common reasons were (1) patient did not carry a diagnosis of metastatic disease (33.3%), (2) treating provider did not comment on the NGS results (25.0%), and (3) provider felt that patient could not tolerate therapy (19.4%). No patients were denied access to level 1 or 2A targeted drugs because of rejection of a nonformulary drug request. CONCLUSION: A substantial minority of patients with NSCLC bearing highly actionable gene variants are not prescribed targeted agents. Further provider- and pathologist-directed educational efforts and implementation of health informatics systems to provide real-time decision support for test ordering and interpretation are needed.

11 April 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HSHanna K. Sanoff
Hanna K. Sanoff
LRLindsay A. Renfro
Lindsay A. Renfro
PPPradeep Poonnen
Pradeep Poonnen
PAPratibha Ambadwar
Pratibha Ambadwar
DSDaniel J. Sargent
Daniel J. Sargent
HMHoward L Mcleod
Howard L Mcleod
Colorectal cancer (CRC) risk is partly conferred by common, low-penetrance single nucleotide polymorphisms (SNPs). We hypothesized that these SNPs are associated with outcomes in metastatic CRC. Six candidate SNPs from 8q24, 10p14, 15q13, 18q21 were investigated for their association with response rate (RR), time to progression (TTP) and overall survival (OS) among 524 patients treated on a phase III clinical trial of first-line chemotherapy for metastatic CRC. rs10795668 was weakly associated with TTP (p = 0.02), but not RR or OS. No other SNPs carried statistically significant HRs for any of the primary outcomes (RR, TTP or OS). Common low-penetrance CRC risk SNPs were not associated with outcomes among patients with metastatic CRC.